Skip to Main Content
Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination
Share

Novel Degrader Shows Anti–Lymphoma and Myeloma Activity

Illustration of a proteasome degrading a ubiquitinated protein.
December 19, 2024

The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.

Yaakov Zinberg
DOI:https://doi.org/10.1158/2159-8290.CD-NW2024-0098
Publisher:American Association for Cancer Research
Article Type: News
You do not currently have access to this content.
Don't already have an account? Register

Advertisement

Breaking
FDA Bans Red Dye No. 3 in Food
AbbVie Inks Deal for T-Cell Engager
GSK Buys Gastrointestinal-Focused Biopharma
View more recent articles
Latest News
Structural Variants Increase Risk of Pediatric Cancers
South Asian Scholars Urge Action on Cancer Inequities
Greater Certainty of Survival Valued Over Speedier Drug Access
View more recent articles
Research Watch
The Zinc-Binding Cysteine Proteome Comprises Targetable Cancer Vulnerabilities
Engineered Focal Oncogene Amplifications Drive Transformation and Progression
Glycolysis Dictates Response to Fasting-Mimicking Diet in Breast Cancer
View more recent articles

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept